Abstract Library

#2843 Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: González Devia D

Authors: Guzman Ruiz Y, Vera Torres A, López Panqueva R, Ardila Duarte G, González Devia D,

Keywords: Pancreatic neuroendocrine tumors, Pancreatic tumor, Prognosis, Neuroendocrine tumor, Gastroenteropancreatic tumor,

#983 Vipomas: Report of Three Cases in Ten Years

Introduction: VIPoma is a rare neuroendocrine tumor (NET) with an incidence of one in 10 million per year. Most cases arise within the pancreas, with others reported in the lungs, colon, liver, adrenals, and neuroganglia.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Moletta L, Milanetto A, Liço V, De Carlo E, Alaggio R,

Keywords: vipoma, neuroendocrine tumors, pancreatic resections,

#836 Grade Increases In Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor

Introduction: The neuroendocrine tumor (NET) proliferation-based grading system (ENETS/WHO) has proved reliable for prognostic stratification of gastroenteropancreatic tumors (GEP). Although anecdotes have been published, no single study has evaluated whether grade changes between primary site and metastases.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Grillo F

Authors: Grillo F, Brisigotti M, Albertelli M, Borra T, Mastracci L,

Keywords: neuroendocrine, grade, Ki-67,

#189 Matrix metalloproteinases (MMPs) and Tissue Inhibitors of Matrix Metalloproteinases (TMIPs) in GEP NET Patients – A Potential Prognostic Biomarkers for Metastases

Introduction: MMPs have the ability to degrade the extracellular matrix and are responsible for tumor invasion and metastases. Higher TIMP-1 levels are associated with low survival rate in some types of cancer.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Blicharz-Dorniak J, Kos-Kudla B, Foltyn W, Zemczak A, Rosiek V,

Keywords: gastroenteropancreatic tumors, MMPs, TIMP1, metastases,

#157 Multiple Endocrine Neoplasia Type 1 (MEN-1), Hadassah-Hebrew University Medical Center experience

Introduction: MEN 1 is an autosomal dominant genetic disorder with a prevalence of 2-4 per 100,000. The main manifestations are parathyroid (PT), gastroenteropancreatic (GEP) and pituitary tumors, but may affect other organ systems as well. MEN 1 is associated with significant morbidity and mortality, with up to 50% dying before the age of 50. Treating MEN 1 patients presents a unique diagnostic and therapeutic challenge.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Kassem S

Authors: Kassem S, Glaser B, Barak D, Fraenkel M, Gross D,

Keywords: MEN-1, hyperparathyroidism, pituitary tumors, gastroenteropancreatic tumors, menin,